CAR T

By addressing challenges related to cost, production efficiency, and patient safety, allogeneic CAR T cell therapies have the potential to make these therapies more accessible and consistent.

This blog will explore how developing customized solutions for system closure and process automation solves key technical bottlenecks, advances the manufacturing of, and ultimately patient access to, these life-saving medicines.